Health Catalyst (NASDAQ:HCAT) General Counsel Sells 29,478 Shares of Company Stock

Key Points

• General Counsel Benjamin Landry sold 29,478 Health Catalyst shares at an average $1.39, worth about $40,974, reducing his stake by 10.48% to 251,894 shares. He also sold 70,000 shares the previous day.
• Health Catalyst reported quarterly revenue of $56.28 million and a loss of $0.03 per share, beating analyst estimates of $55.39 million in revenue and a $0.05 loss per share.
• Analyst sentiment remains cautious: the stock has a consensus “Reduce” rating and a $2.01 price target. Shares recently traded at $1.50.

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) General Counsel Benjamin Landry sold 29,478 shares of the firm's stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $1.39, for a total transaction of $40,974.42. Following the completion of the transaction, the general counsel owned 251,894 shares of the company's stock, valued at $350,132.66. This trade represents a 10.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Benjamin Landry also recently made the following trade(s):

• On Wednesday, November 11th, Benjamin Landry sold 70,000 shares of Health Catalyst stock. The shares were sold at an average price of $1.43, for a total transaction of $100,100.00.

Health Catalyst Stock Performance

Health Catalyst stock traded up $0.14 during midday trading on Friday, reaching $1.50. 465,291 shares of the stock were exchanged, compared to its average volume of 920,868. Health Catalyst, Inc. has a 52 week low of $0.96 and a 52 week high of $3.02. The firm has a market cap of $114.22 million, a PE ratio of -0.53 and a beta of 1.52. The company's fifty day moving average is $1.69 and its 200-day moving average is $1.69.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.02. Health Catalyst had a negative net margin of 74.24% and a negative return on equity of 4.84%. The firm had revenue of $56.28 million during the quarter, compared to the consensus estimate of $55.39 million. On average, sell-side analysts anticipate that Health Catalyst, Inc. will post -0.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Health Catalyst in a research report on Monday, October 26th. Canaccord Genuity Group cut Health Catalyst from a "buy" rating to a "hold" rating and reduced their target price for the stock from $3.00 to $1.80 in a research report on Thursday, August 20th. Wells Fargo & Company decreased their target price on Health Catalyst from $1.75 to $1.50 and set an "equal weight" rating on the stock in a research note on Thursday, August 13th. Finally, Citigroup lowered their price target on Health Catalyst from $2.50 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday, August 11th. Five research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Reduce" and a consensus target price of $2.01.

Institutional Investors Weigh In On Health Catalyst

Several hedge funds have recently bought and sold shares of the stock. Palogic Value Management L.P. purchased a new position in Health Catalyst in the 2nd quarter worth approximately $9,796,000. BlackRock Inc. bought a new position in shares of Health Catalyst in the 2nd quarter worth $3,654,000. Hsbc Holdings PLC bought a new position in shares of Health Catalyst in the 2nd quarter worth $809,000. Squarepoint Ops LLC raised its position in shares of Health Catalyst by 1,214.8% during the 2nd quarter. Squarepoint Ops LLC now owns 400,210 shares of the company's stock valued at $796,000 after buying an additional 369,772 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Health Catalyst during the 1st quarter valued at $276,000. 85.00% of the stock is currently owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions are designed to help providers use clinical, operational, and financial data to support decision-making and improve care delivery. The company's offerings include a data platform that brings together information from multiple sources, analytics applications for healthcare workflows, and professional services. These services can include implementation, data management, and support for organizations developing and applying analytics programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.